Paula Renata Bueno Campos Canella

Mrs. Paula Renata Bueno Campos Canella

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
PCPaula Renata Bueno Campos Canella
Paula Renata Bueno Campos Canella
RBRicardo Barini
Ricardo Barini
PCPatricia de Oliveira Carvalho
Patricia de Oliveira Carvalho
DRDaniela Soares Razolli
Daniela Soares Razolli
Altered immune and/or inflammatory response plays an important role in cases of recurrent pregnancy loss (RPL) and repeated implantation failure (RIF). Exacerbation of the maternal immune response through increased NK cell activity and inflammatory cytokines can cause embryo rejection leading to abortion or embryo implantation failure. Immunosuppressors or immunomodulators can help or prevent this condition. Currently, lipid emulsion therapy (LET) has emerged as a treatment for RPL and RIF in women with abnormal NK cell activity, by decreasing the exacerbated immune response of the maternal uterus and providing a more receptive environment for the embryo. However, the mechanisms by which the intralipid acts to reduce NK cell activity are still unclear. In this review, we focus on the studies that conducted LET to treat patients with RPL and RIF with abnormal NK cell activity. We find that although some authors recommend LET as an effective intervention, more studies are necessary to confirm its effectiveness in restoring NK cell activity to normal levels and to comprehend the underlying mechanisms of the lipids action in ameliorating the maternal environment and improving the pregnancy rate.

15 January 2023 in Catalysts
Verified
Journal Article
Open access
PDF file
PGPedro Henrique Dias Garcia
Pedro Henrique Dias Garcia
TCTales Alexandre Costa-Silva
Tales Alexandre Costa-Silva
MGMartí Morera Gómez
Martí Morera Gómez
Fabiano Jares ContesiniFabiano Jares Contesini
Fabiano Jares Contesini
PCPaula Renata Bueno Campos Canella
Paula Renata Bueno Campos Canella
PCPatricia de Oliveira Carvalho
Patricia de Oliveira Carvalho
The enzyme L-asparaginase (L-asparagine amidohydrolase) catalyzes the breakdown of L-asparagine into aspartate and ammonia, which leads to an anti-neoplastic activity stemming from its capacity to deplete L-asparagine concentrations in the bloodstream, and it is therefore used in cases of acute lymphoblastic leukemia (ALL) to inhibit malignant cell growth. Nowadays, this anti-cancer enzyme, largely produced by Escherichia coli, is well established on the market. However, E. coli L-asparaginase therapy has side effects such as anaphylaxis, coagulation abnormality, low plasma half-life, hepatotoxicity, pancreatitis, protease action, hyperglycemia, and cerebral dysfunction. This review provides a perspective on the use of filamentous fungi as alternative cell factories for L-asparaginase production. Filamentous fungi, such as various Aspergillus species, have superior protein secretion capacity compared to yeast and bacteria and studies show their potential for the future production of proteins with humanized N-linked glycans. This article explores the past and present applications of this important enzyme and discusses the prospects for using filamentous fungi to produce safe eukaryotic asparaginases with high production yields.

16 February 2023 in Life
Verified
Journal Article
Open access
PDF file
MSMariana Alves Sobreiro
Mariana Alves Sobreiro
ATAdriana Della Torre
Adriana Della Torre
MAMaria Elisa Melo Branco de Araújo
Maria Elisa Melo Branco de Araújo
PCPaula Renata Bueno Campos Canella
Paula Renata Bueno Campos Canella
JCJoão Ernesto de Carvalho
João Ernesto de Carvalho
ARAna Lucia Tasca Gois Ruiz
Ana Lucia Tasca Gois Ruiz
The bioavailability of glucoside flavonoids is influenced by the nature of the sugar, glucosides being absorbed faster than rhamnoglucosides, for example. One strategy to enhance the bioavailability is enzymatic hydrolysis. In this study, some kinetic parameters of hesperidinase-mediated hydrolysis of rutin were evaluated using an UHPLC/QTOF-MSE analysis of the products of a bioconversion reaction. The resulting hydrolyzed rutins (after 4, 8 and 12 h of reaction) were submitted to anti-proliferative and Cytokinesis-Block Micronucleus (CBMN) assays in CHO-K1 cells. In the hesperidinase-mediated hydrolysis, the final concentration of quercetin-3-O-glucoside (Q3G) was directly proportional to the rutin concentration and inversely proportional to the reaction time. At an anti-proliferative concentration (2.5 μg/mL), hydrolyzed rutin derivatives did not show a mutagenic effect, except for the sample with a higher content of Q3G (after 4 h of the enzymatic hydrolysis of rutin). Moreover, the higher Q3G content in hydrolyzed rutin protected the CHO-K1 cells 92% of the time against methyl methanesulfonate-induced mutagenic damage. These results suggested that the anti-mutagenic effect of hydrolyzed rutin might be related to antioxidant and cell death induction. Presenting a good lipophilicity/hydrophilicity ratio, together with antioxidant and anti-mutagenic activities, the hesperidinase-mediated hydrolyzed rutin seemed to be a promisor raw material for the development of food supplements.